Received Apr 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | N/A | 013009 | IM / LA |
| TDAP | TDAP (ADACEL) | SANOFI PASTEUR | N/A | U8115AA | IM / LA |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 4H79Y | IM / RA |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | 013009 | OT / LA |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | U8115AA | OT |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4H79Y | OT |
After the 3rd vaccine (order was shingrix, capvaxive, adacel) patient incoherent then fainted. I administered one dose of epinephrine 0.3mg.; After the 3rd vaccine (order was shingrix, capvaxive, adacel) patient incoherent then fainted. I administered one dose of epinephrine 0.3mg.; Information has been received from the Health Authority via VAERS (VAERS ID: 2828448-1). This spontaneous report was received from a Regulatory Authority and refers to a(n) 57-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies included citalopram 40 mg. On 26-Feb-2025, the patient started therapy with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (lot # as reported 013009, administered by Intramuscular route in Left Arm (strength, dose, dose number, vaccination scheme, and expiration date were not reported), as prophylaxis. On 26-Feb-2025, the patient started therapy with Diphtheria vaccine toxoid;Pertussis vaccine acellular 5-component;Tetanus vaccine toxoid (ADACEL) lot #U8115AA, administered by Intramuscular route in the left arm (strength, dose, dose number, vaccination scheme, and expiration date was not reported), as prophylaxis. On 26-Feb-2025, the patient started therapy with Varicella zoster vaccine rgE (CHO) (SHINGRIX) lot #4H79Y, administered by Intramuscular route in the right arm (strength, dose, dose number, vaccination scheme, and expiration date were not reported), as prophylaxis. On 26-Feb-2025, after the 3rd vaccine (order was shingrix, capvaxive, adacel) patient became incoherent then fainted; then, it was administered one dose of epinephrine 0.3mg. On 26-Feb-2025, the patient recovered from the events. The reporter did not assess the causal relationship between the events and the suspect vaccines. Upon internal review syncope was determined to be important medical event.
citalopram 40 mg